Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

NCT04810611 : A Phase Ib, Multicenter, Open-label Platform Study of Select Drug Combinations in Adult Patients With Lower Risk (Very Low, Low, or Intermediate Risk) Myelodysplastic Syndrome

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

OnePhase One

18+Age Over 18

Blood<br/>CancersCancer LocationBlood
Cancers

Systemic therapy | Blood / Myeloma / LymphomaMyelodysplasia

Trial Overview Read MoreRead more

This phase I study is evaluating how safe and tolerable different targeted therapies (MBG453, NIS793 and canakinumab) are alone, or combined, in people with lower risk myelodysplastic syndromes..
 

This trial is treating patients with very low, low and intermediate risk myelodisplastic syndrome.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have been diagnosed with cancer, but have not received any treatment.
  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase Ib, Multicenter, Open-label Platform Study of Select Drug Combinations in Adult Patients With Lower Risk (Very Low, Low, or Intermediate Risk) Myelodysplastic Syndrome

Commercial Sponsor

Novartis Pharmaceuticals

Summary

Eligible participants will be assigned to one of five experimental arms. In Experimental Arm 1, participants will receive MBG453 alone, every 4 weeks, to confirm safety and tolerability of RD. In Experimental Arm 2, participants will receive NIS793 alone, every 3 weeks, to establish RD in this indication and confirm safety and tolerability. In Experimental Arm 3, participants will receive canakinumab alone, every 4 weeks, to confirm safety and tolerability of RD. In Experimental Arm 4, participants will receive MBG453 + NIS793 combined treatment every 3 weeks to confirm safety and tolerability of combination RD. In Experimental Arm 5 MBG453 + canakinumab combined treatment every 4 weeks to confirm safety and tolerability of combination RD.

Recruiting Hospitals Read MoreRead more

Alfred Hospital, Malignant Haematology & Stem Cell Transplantation Service
Prahran
Ms Nola Kennedy
n.kennedy@alfred.org.au
03 9076 2217

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next